巨子生物在收入增长方面表现如何？ 巨子生物 摘要 巨子生物依托重组胶原蛋白技术，通过可复美和可丽金等品牌在美妆赛 道实现差异化竞争，可复美保持快速增长，可丽金调整后重回增长轨道， 线上渠道表现强劲。 公司通过控制达播业务的毛销差，采用融合模式与达人合作，优化费用 结构，有效应对短期舆情事件，确保经营利润率不受大幅影响。 双十一期间，巨子生物稳定商品划线价，优惠成本主要由平台或达人承 担，公司选择性参与活动，并通过年框协议锁定与头部达人的合作条款， 确保费用端稳定。 公司线上收入占比高达 75%，并预计提升至 80%以上，主要采用 GTC 模式；线下渠道通过经销模式，早期布局医院端，扩展药店 SKU，孵化 新品牌"可遇"承接医院端向家庭消费场景外溢。 公司通过精准筛选达人、优化投流策略控制费销比，避免盲目合作头部 达人，提高转化效率，并主动控制头部达人的 GMV 占比，提升中腰部 达人的投放效率。 Q&A 巨子生物的核心竞争力是什么？ 巨子生物是国内最早研发并全球最早量产重组胶原蛋白的企业。公司以生产重 组胶原蛋白为核心技术，聚焦功能护肤品、医疗器械和功能性食品三大应用板 块。公司拥有全球最全面的胶原蛋白分子库 ...

Group 1: Financial Performance - The company reported a revenue of 3.11 billion, representing a year-on-year increase of 22.5%, and a net profit attributable to the parent company of 1.18 billion, up 20%, meeting market expectations [1] - Gross margin stood at 81.7%, down 0.7 percentage points, while net profit margin was 38.0%, down 0.6 percentage points [1] - Revenue breakdown shows 82% from the brand "可复美" and 16% from "可丽金", with "可复美" generating 2.54 billion (up 23%) and "可丽金" 503 million (up 27%) [1] Group 2: Strategic Initiatives - The company is expanding production capacity and global presence by adding new production lines for collagen, cosmetics, and medical devices, and constructing new factories for medical devices and health products [2] - A new regional headquarters has been established in Xiamen Free Trade Zone, which will serve as a business settlement center, manufacturing base, and cross-border trade platform [2] - The company is actively participating in major exhibitions and has made significant inroads into markets like Hong Kong and Malaysia, marking a breakthrough in overseas sales [2] Group 3: R&D and Supply Chain Management - The core R&D and management team remains stable, providing a solid foundation for the company's development [2] - The company is focusing on functional skincare and medical devices, with several new products in the R&D or registration phase, expected to launch in the first half of next year [2] - Supply chain management capabilities are being optimized through long-term partnerships with quality raw material suppliers and digital management of production, warehousing, and logistics [2] Group 4: Investment Outlook - The company is positioned as a leader in the application of synthetic biology in the beauty and medical fields, with high technical barriers and increasing brand recognition [3] - Short-term performance is stabilizing, while long-term growth is supported by new product launches and deeper global expansion [3] - Projected net profits for 2025-2027 are 2.502 billion, 3.008 billion, and 3.655 billion, corresponding to PE ratios of 22.0, 18.3, and 15.1, respectively, with a target price of 69.04 HKD for 2025 [3]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 69.04 HKD [2][9]. Core Insights - The company is experiencing a recovery in its data, indicating stabilization in its performance. The growth momentum is expected to be strong due to new product launches and global expansion efforts [9]. - The company is a leader in the application of synthetic biology in the beauty and medical fields, with a high technical barrier and increasing brand recognition [9]. - Financial projections indicate significant revenue growth, with total revenue expected to reach 6,907 million HKD in 2025, representing a year-on-year growth of 24.7% [5][10]. Financial Summary - Total revenue projections for the company are as follows: - 2024: 5,539 million HKD - 2025: 6,907 million HKD - 2026: 8,495 million HKD - 2027: 10,312 million HKD - Net profit projections are: - 2024: 2,062 million HKD - 2025: 2,502 million HKD - 2026: 3,008 million HKD - 2027: 3,655 million HKD - Earnings per share (EPS) are projected to increase from 2.01 HKD in 2024 to 3.41 HKD in 2027 [5][10][11]. Market Position and Strategy - The company is expanding its production capacity and global footprint, including establishing a regional headquarters in Xiamen and participating in international trade shows [9]. - The core team remains stable, focusing on continuous product development, particularly in functional skincare and medical devices [9]. - Supply chain management is being optimized to enhance cost control and market responsiveness, ensuring stable growth [9].

Investment Rating - The report maintains a "Positive" outlook on the beauty and personal care industry, highlighting the resilience of domestic brands and the impact of new consumption trends [2]. Core Insights - The beauty and personal care sector experienced a robust recovery in H1 2025, with a retail sales growth of 2.9%, reversing the previous decline due to favorable consumption policies and improved income expectations [5][6]. - Domestic brands are gaining market share, with top local brands now competing closely with international counterparts, indicating a significant shift in consumer preferences [10][11]. - The report categorizes companies into three groups based on performance: those with strong brand matrices benefiting from multi-brand strategies, those capitalizing on consumer trends like domestic brands and collagen products, and those showing signs of strategic improvement [20][23]. Summary by Sections Industry Overview - The beauty market is projected to grow steadily, with a forecasted retail sales decline of 1.1% in 2024, followed by a recovery in H2 2025 [5][6]. - The domestic market share is expected to increase, with local brands achieving significant breakthroughs in both skincare and makeup segments [10][11]. Company Performance - **Cosmetics Sector**: - Major companies like Up Beauty and Proya reported revenue growth of 17.3% and 7.2% respectively in H1 2025, with net profits increasing by 30.6% and 13.8% [20][21]. - Other notable performers include Marubi and Water Sheep, with revenue growth of 30.8% and 9.0% respectively [21][22]. - **Personal Care Sector**: - Companies like Ruibin and Zhenjia showed remarkable growth, with Ruibin's revenue increasing by 67.6% and Zhenjia's by 157.11% in H1 2025 [5][20]. - **Medical Aesthetics Sector**: - Companies like Aimeike and Langzi reported mixed results, with Aimeike's revenue declining by 21.6% while Langzi's net profit surged by 64.1% [20][24]. Investment Recommendations - The report recommends investing in companies with strong brand matrices and low PE multiples, such as Up Beauty and Proya, as well as those benefiting from the Douyin traffic boost like Marubi and Water Sheep [20][24]. - It also suggests focusing on high-value segments and innovative products from brands like Ruibin and Furuida, and highlights opportunities in the maternal and infant sector with companies like Shengbeila and Haiziwang [20][24].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - The company reported a revenue of 3.11 billion HKD for H1 2025, representing a year-on-year growth of 22.5%. The net profit attributable to shareholders was 1.18 billion HKD, up 20.2% year-on-year, while the adjusted net profit reached 1.21 billion HKD, reflecting a 17.4% increase [2][4]. Summary by Sections Revenue Performance - In H1 2025, the revenue breakdown by product categories showed medical dressings, functional skincare, and health food generating revenues of 690 million HKD, 2.41 billion HKD, and 10 million HKD respectively, with year-on-year growth rates of 17%, 24%, and 16% [6]. - By brand, the revenues for 可复美, 可丽金, and other brands were 2.54 billion HKD, 500 million HKD, and 60 million HKD respectively, with growth rates of 23%, 27%, and -10% [6]. - Channel-wise, revenues from DTC, e-commerce direct sales, offline direct sales, and distribution were 1.82 billion HKD, 390 million HKD, 120 million HKD, and 790 million HKD respectively, with year-on-year growth rates of 13%, 134%, 74%, and 12% [6]. Profitability - The net profit margin slightly decreased by 0.7 percentage points in H1 2025, attributed to a 0.7 percentage point decline in gross margin and changes in sales, management, and R&D expense ratios [6]. - The overall expense ratio narrowed by 1.6 percentage points, while the income tax expense increased by approximately 87.06 million HKD year-on-year [6]. Investment Outlook - The company is expected to maintain healthy growth throughout the year, with projected adjusted net profits of 2.55 billion HKD, 3.00 billion HKD, and 3.65 billion HKD for 2025, 2026, and 2027 respectively, corresponding to PE valuations of 23, 19, and 16 times [6].

Core Viewpoint - The company demonstrates resilience and brand strength with revenue and profit growth in H1 2025 despite external challenges, and is expected to accelerate growth in H2 due to upcoming promotional activities [1] Group 1: Financial Performance - In H1 2025, the company's revenue and profit increased, with revenue growth rates of 22.7% for 可复美 and 26.9% for 可丽金 [1] - The GMV for 可复美 and 可丽金 in July reached 1.72 billion and 0.19 billion respectively, showing year-on-year growth of 48% and 77% [1] - The company maintains its profit forecast with expected net profits of 26.00 billion, 32.03 billion, and 38.12 billion for 2025-2027 [3] Group 2: Product and Innovation - The company has obtained exclusive patents for new products, including a restructured IV type collagen and ginsenoside-rich fermented ginseng products, enhancing its R&D capabilities [2] - The brand is actively promoting its products through various channels, including a successful live-streaming event on September 8 that generated over 16 million in GMV [1][2] Group 3: Market Expansion - The company is expanding its market presence, having entered the Malaysian market and established a joint venture to target Southeast Asia [2] - The brand has also made inroads into the South Korean and French markets, with product launches in key retail locations [2] Group 4: Valuation and Target Price - The company maintains a target price of 85.0 HKD for 2025, reflecting a PE ratio of 31 times, adjusted from a previous target of 82.50 HKD [3] - The valuation considers the company's successful brand promotion and overseas channel development [3]

Core Viewpoint - The competitive landscape of the domestic beauty industry has shifted, with Juzhibio entering the top three and Betaini dropping out of the top five, highlighting significant changes in revenue and profit dynamics among key players [2][3]. Revenue Performance - Prolayya leads with a revenue of 5.362 billion yuan, followed by Shangmei with 4.108 billion yuan, and Juzhibio at 3.103 billion yuan, which represents a year-on-year increase of 22.55% [3][4]. - Betaini's revenue stands at 2.372 billion yuan, reflecting a decline of 15.43% compared to the previous year, marking a significant drop from its previous position as the third-largest player [3][4]. Profitability Analysis - Juzhibio reported a net profit of 1.182 billion yuan, up 20.2% year-on-year, while Betaini's net profit plummeted to 247 million yuan, a decrease of nearly 50% [4][8]. - The profit margin disparity is stark, with Juzhibio achieving a net profit margin of 37.9%, compared to Betaini's 10.4% [8][9]. Brand Strategy and Market Positioning - Juzhibio has successfully developed multiple sub-brands, such as Kefu Mei and Keli Jin, which contribute significantly to its revenue, while Betaini struggles with its primary brand, Weinuona, which has seen declining sales [4][15]. - The strategic focus on brand diversification and effective channel management has allowed Juzhibio to mitigate market fluctuations, whereas Betaini remains heavily reliant on a single brand [15][16]. Sales and Marketing Efficiency - Juzhibio maintains a lower sales expense ratio of 34.0%, while Betaini's sales expenses have surged to 54.2%, significantly impacting its profitability [8][9]. - The average selling price of Betaini's skincare products has decreased, contributing to its revenue decline, while Juzhibio's pricing strategy has allowed it to maintain higher margins [5][6]. Channel Development - Both companies initially built their brands through professional channels, but Juzhibio has expanded its direct sales and online presence more effectively than Betaini, which has seen a decline in offline sales [13][14]. - Juzhibio's direct sales accounted for 74.7% of its revenue, with significant growth in both online and offline channels, contrasting with Betaini's heavy reliance on e-commerce, which has faced challenges [13][14]. Future Outlook - The beauty industry consensus is shifting towards creating a brand matrix to diversify risk and extend growth, a strategy that Juzhibio has successfully implemented, while Betaini needs to develop additional brands to remain competitive [15][16].

Company Overview - The company has organized a post-performance NDR communication, indicating that short-term event impacts are gradually dissipating, with self-broadcasting continuing to show healthy and strong growth. Brand acquisition and influencer marketing are gradually recovering, suggesting that the upcoming Double Eleven shopping festival may further restore brand momentum [1][2] - The company is recognized as a leader in collagen products, with a strong outlook for future growth, and is advised to strategically position itself for the recovery opportunities during the Double Eleven season [1] Short-term Performance - In the first half of the year, the company optimized its self-broadcasting matrix and strengthened product selection strategies, maintaining good growth despite short-term event impacts. Monitoring data shows that the brand "可复美" achieved over 50% GMV growth in self-broadcasting and product card sales on Douyin during July and August, with repurchase rates remaining high, indicating limited impact on loyal customers [1] - Influencer marketing faced significant short-term impacts but is gradually recovering, with "可复美" achieving approximately 23% market share in influencer marketing during the industry off-peak period of July and August, showing a rebound from the event impact phase [1][2] Product Development - The company has successfully expanded its brand audience and product efficacy through single product cultivation since its listing. The foundational R&D and enhanced market insights have led to continuous improvement in the product development chain. The "可复美" brand has established multiple product lines, including collagen repair series and focus series, with the collagen repair series performing well in the first half of the year [2] - The core products of the "可丽金" brand also showed strong online growth, indicating a solidified market presence. The company's ability to cultivate single products is expected to continue supporting long-term brand growth [2] Upcoming Opportunities - As the Double Eleven shopping season approaches, the recovery of influencer marketing is expected to drive brand momentum back on track. The company maintains communication with top influencers, which has yielded positive results. Increased influencer marketing frequency is anticipated to boost marketing efforts and accelerate brand acquisition [2] - The company has made positive progress in obtaining certifications for three types of medical devices since the beginning of the year, which is expected to contribute to incremental growth in the future [2] Financial Forecast - The company maintains a profit forecast of 2.5 billion to 3.2 billion CNY for 2025-2026, with the current stock price corresponding to a P/E ratio of 21x for 2025 and 17x for 2026. The company maintains an outperform rating and a target price of 82 HKD, indicating a potential upside of 50% [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company reported a revenue of RMB 3.11 billion for the first half of 2025, representing a year-over-year increase of 22.5%. The net profit attributable to shareholders was RMB 1.18 billion, up 20.2% year-over-year [8]. - The company's main brand, 可复美, achieved revenue of RMB 2.54 billion, growing 22.7% year-over-year, while the 可丽金 brand saw revenue of RMB 0.50 billion, increasing by 26.9% year-over-year. Despite facing a public relations issue in May, sales have shown recovery [8]. - The direct sales channel generated RMB 2.33 billion in revenue, a year-over-year increase of 26.5%, with its revenue share rising by 2.3 percentage points [8]. - The overall gross margin for the first half of 2025 was 81.7%, a slight decrease of 0.7 percentage points year-over-year, attributed to product category expansion and rising costs [8]. - The report forecasts net profits of RMB 2.65 billion, RMB 3.29 billion, and RMB 4.02 billion for 2025, 2026, and 2027, respectively, with year-over-year growth rates of 28.3%, 24.2%, and 22.3% [8][10]. Financial Summary - The company is projected to achieve a net profit of RMB 2.65 billion in 2025, with an earnings per share (EPS) of RMB 2.47, reflecting a year-over-year increase of 17.67% [10]. - The price-to-earnings (P/E) ratio is expected to decrease from 21 in 2025 to 14 by 2027, indicating a potentially undervalued stock [10]. - The dividend per share (DPS) is projected to increase from RMB 1.38 in 2025 to RMB 2.10 by 2027, with a dividend yield rising from 2.72% to 4.14% over the same period [10].

Group 1 - The company maintains profit forecasts of 2.5 billion and 3.2 billion for 2025 and 2026, respectively, with current stock price corresponding to 21x and 17x P/E for those years, indicating a 50% upside potential [1] - The company is viewed positively as a leader in collagen protein restructuring, with recommendations to strategically position for the upcoming Double Eleven shopping season [1] - Short-term impacts from events are gradually dissipating, with self-broadcasting continuing to show strong growth and brand acquisition efforts recovering [2][3] Group 2 - The company has successfully optimized its self-broadcasting matrix and product selection strategy, maintaining good growth despite short-term event impacts, with GMV growth exceeding 50% for the 可复美 brand in July and August [3] - The company has established multiple product lines under the 可复美 brand, including collagen repair series and focus series, with strong performance in the collagen repair series [4] - As the Double Eleven shopping season approaches, increased broadcasting frequency is expected to drive brand momentum and recovery in customer acquisition [5]